Study On The Expression And Clinical Significance Of Fli-1in Endometrial Carcinoma

Objective: Increasing number of studies showed Fli-1(Friend leukemia virusintegration1) plays an important role in oncogenesis and neovascularization in varioustumors. Our study investigated the expression of Fli-1in endometrial carcinoma, andanalyzed the correlation between the level of Fli-1expression and clinical indicators, so asto throw light upon molecular diagnosis, prognositic judgement, and molecular targetedtherapy of endometrial carcinoma.Methods: We collected16endometrial carcinoma specimens from patients thatundergone hysterectomy in the first hospital attached to Jilin University. The specimenswere required to contain both tumor tissue and the adjacent normal tissue. The endometrialcarcinoma specimens were classified according to FIGO2009surgical-pathological staging.There were6,5, and5cases in stage I, stage II, and stage III, respectively. Refering to thehistological grading, there were8,5,3cases of G1, G2, and G3, respectively. The age ofthe patients ranged from26to72, the median being50.5. Immunohistochemistry stainingmethod was applied to test the expression of Fli-1. The level of Fli-1expression was scoredaccording to the staining, so as to make a quantitive comparison between the subgroups.Statistical analysis was performed using SPSS17.0software package. Statistical differencewas established at the P<0.05level, and significant statistical difference at the P<0.01level.Results:1. Positive expression of Fli-1in endometrial carcinoma was located in thecytoplasm；2. The positive rate of Fli-1was0%and75%,and the score of Fli-1was0.231±0.2496and1.550±0.7607respectively in the paracarcinoma tissue and the endometrialcarcinoma tissue. Both the positive rate and score of Fli-1were higher in the endometrialcarcinoma tissue than in the paracarcinoma tissue (P <0.01);3. The score of Fli-1in endometrial carcinoma was1.067±0.4131in stage I,1.340±0.7603in stage II, and2.340±0.4393in stage III. The level of Fli-1expression in stage IIIwas significantly higher than stage I and stage II (P <0.01); 4. The score of Fli-1in endometrial carcinoma was1.323±0.6234in p53negativegroup, and2.533±0.4726in p53positive group. The level of Fli-1expression in p53positive group was significantly higher than in p53negative group (P <0.01);5. There was no correlation between Fli-1expression and clinical indicators such aspathological type, histological grading, infiltrating depth of muscular layer, involvement ofcervix, age of onset, ER, PR, serum CA125in endometrial carcinoma (P>0.05).Conclusion: Both the positive rate and score of Fli-1were higher in the endometrialcarcinoma tissue than in the paracarcinoma tissue. There was a trend that Fli-1expressionincreased along with surgical-pathological stage elevated. The level of Fli-1expression inp53positive group was significantly higher than in p53negative group. Results aboveindicate that Fli-1might participate in the oncogenisis and progression of endometrialcarcinoma. Thus we presume Fli-1to be an effective indicator in clinical diagnosis,prognositic judgement, and reference for therapy of endometrial carcinoma.